Skip to main content
SpringerLink
Log in

Breakthrough disease

  • Chapter
  • First Online:
Case Studies in Multiple Sclerosis

  • 1029 Accesses

Abstract

A 23-year-old female presented to the clinic for routine follow-up for relapsing remitting multiple sclerosis (RRMS). She was originally diagnosed 2 years prior after a one-month episode of left hand numbness, followed by acute optic neuritis in the right eye, which left her with a significant residual visual acuity deficit despite acute treatment with high-dose intravenous steroids.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Rotstein DL, Healy BC, Malik MT, Chitnis T, Weiner HL. Evaluation of no evidence of disease activity in a 7-year longitudinal multiple sclerosis cohort. JAMA Neurol. 2015;72:152-158.

    Google Scholar 

  2. Stangel M, Penner IK, Kieseier BC. Defining the new end point for multiple sclerosis treatment. JAMA Neurol. 2014;71:1056-1057.

    Google Scholar 

  3. Barkhof F, Simon JH, Fazekas F, et al. MRI monitoring of immunomodulation in relapse-onset multiple sclerosis trials. Nat Rev Neurol. 2012;8:13-21.

    Google Scholar 

  4. Sormani MP, Li DK, Bruzzi P, et al. Combined MRI lesions and relapses as a surrogate for disability in multiple sclerosis. Neurology. 2011;77:1684-1690.

    Google Scholar 

  5. Kinkel RP, Simon JH, O’Connor P, Hyde R, Pace A. Early MRI activity predicts treatment nonresponse with intramuscular interferon beta-1a in clinically isolated syndrome. Mult Scler Relat Disord. 2014;3:712-719.

    Google Scholar 

  6. Prosperini L, Gallo V, Petsas N, Borriello G, Pozzilli C. One-year MRI scan predicts clinical response to interferon beta in multiple sclerosis. Eur J Neurol. 2009;16:1202-1209.

    Google Scholar 

  7. Rio J, Comabella M, Montalban X. Predicting responders to therapies for multiple sclerosis. Nat Rev Neurol. 2009;5:553-560.

    Google Scholar 

  8. Rudick RA, Lee JC, Simon J, Ransohoff RM, Fisher E. Defining interferon beta response status in multiple sclerosis patients. Ann Neurol. 2004;56:548-555.

    Google Scholar 

  9. Uhthoff W. Untersuchungen uber die bei der multiplen Herdsklerose vorkommenden Augenstorungen. Arch Psychiatr Nervenkr. 1890;21:303-420. German.

    Google Scholar 

  10. Frohman TC, Davis SL, Beh S, Greenberg BM, Remington G, Frohman EM. Uhthoff‘s phenomena in MS–clinical features and pathophysiology. Nat Rev Neurol. 2013;9:535-540.

    Google Scholar 

  11. Fromont A, Benatru I, Gignoux L, Couvreur G, Confavreux C, Moreau T. [Long-lasting and isolated Uhthoff‘s phenomenon after effort preceding multiple sclerosis]. Rev Neurol (Paris). 2010;166:61-65. French.

    Google Scholar 

  12. Rio J, Porcel J, Tellez N, et al. Factors related with treatment adherence to interferon beta and glatiramer acetate therapy in multiple sclerosis. Mult Scler. 2005;11:306-309.

    Google Scholar 

  13. Clerico M, Barbero P, Contessa G, Ferrero C, Durelli L. Adherence to interferon-beta treatment and results of therapy switching. J Neurol Sci. 2007;259:104-108.

    Google Scholar 

  14. Cohen B. Adherence to disease-modifying therapy for multiple sclerosis. Int J MS Care. 2006;(suppl):32-37.

    Google Scholar 

  15. Turner AP, Kivlahan DR, Sloan AP, Haselkorn JK. Predicting ongoing adherence to disease modifying therapies in multiple sclerosis: utility of the health beliefs model. Mult Scler. 2007;13:1146-1152.

    Google Scholar 

  16. Costello K, Kennedy P, Scanzillo J. Recognizing nonadherence in patients with multiple sclerosis and maintaining treatment adherence in the long term. Medscape J Med. 2008;10:225.

    Google Scholar 

  17. Coyle PK. Switching therapies in multiple sclerosis. CNS Drugs. 2013;27:239-247.

    Google Scholar 

  18. Healy BC, Glanz BI, Stankiewicz J, Buckle G, Weiner H, Chitnis T. A method for evaluating treatment switching criteria in multiple sclerosis. Mult Scler. 2010;16:1483-1489.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Duke University School of Medicine, Durham, North Carolina, USA

    Chris Eckstein

Authors
  1. Chris Eckstein
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. McGill University , MONTREAL, Québec, Canada

    Paul S. Giacomini

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Eckstein, C. (2017). Breakthrough disease. In: Giacomini, P. (eds) Case Studies in Multiple Sclerosis. Adis, Cham. https://doi.org/10.1007/978-3-319-31190-6_5

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-31190-6_5

  • Published:

  • Publisher Name: Adis, Cham

  • Print ISBN: 978-3-319-31188-3

  • Online ISBN: 978-3-319-31190-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation